Compare Boston Scientific Corporation (BSX) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Lamb Weston Holdings Inc — how do they compare? Boston Scientific Corporation trades at $51.59 (market cap $74.19B), while Lamb Weston Holdings Inc trades at $53.1 (market cap $7.23B). The key difference: Boston Scientific Corporation is far larger — about 10.3× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | LW | |
|---|---|---|
Market Cap | $74.19B | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $66.57 |
52-Week Low | $42.63 | $38.48 |
Enterprise Value | $86.27B | $11.10B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Lamb Weston (LW) trades at $53.04, up 2.37% today, near its consensus price target of $53.86. The stock shows a bullish technical trend with consistent earnings beats in recent quarters, including Q2 2026 EPS of $0.87 versus $0.626 expected. Revenue reached $6.45 billion in 2025, though net income margin declined to 4.39%. Analyst sentiment is mixed with 31.58% buy ratings, while institutional investors like Dimensional Fund Advisors increased holdings by 28.1% in Q1 2026 (SEC filing, 2026-07-29).
The outlook is cautiously optimistic given operational improvements and cost savings, but risks include international demand pressures and elevated costs. The stock offers a 3.1% dividend yield, with fiscal 2027 guidance projecting 1%-2% sales growth. Further upside depends on sustaining North American volume growth and margin stabilization amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
